Better Health for All

Ascentage Pharma's core business is dedicated to discovering, developing, and commercializing innovative therapies for severe conditions such as cancer, chronic hepatitis B, and age-related diseases, addressing unmet medical needs. Its product pipeline, including Olverembatinib for various cancers and Lisaftoclax for myelodysplastic syndromes (MDS), focuses entirely on providing substantial health benefits. Olverembatinib has received multiple designations, including Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track from regulatory bodies, and is included in the China National Reimbursement Drug List (NRDL)

and US NCCN Guidelines for CML . The company has obtained a total of 16 Orphan Drug Designations from the US FDA and one from the EMA for four investigational drug candidates . There is no evidence of any products or services with established negative health outcomes, and its therapeutic drugs for serious medical conditions do not have addiction potential. To improve access, Olverembatinib is included in the China NRDL and 114 supplemental insurance plans , and the company operates a Named Patient Program (NPP) for access in countries where the drug is not yet commercially available . Ascentage Pharma has received significant investment, including a US$75 million equity investment and a US$100 million option payment from Takeda , with a total collaboration value of US$1.3 billion , and is designated for multiple Major National R&D Projects, including one for the prevention and treatment of infectious diseases . The company conducts ongoing clinical trials, presents results at major medical conferences , and has received regulatory clearances for Phase III studies . It holds 520 issued patents, with 367 outside China .

Fair Money & Economic Opportunity

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies.

The provided articles detail its financial performance, drug approvals, and named patient programs for its pharmaceutical products. There is no evidence that the company engages in financial services such as lending, insurance, money movement, or storage for consumers. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company does not offer financial products or services.

Fair Pay & Worker Respect

No quantitative data or specific, concrete facts were found across the provided articles to assess Ascentage Pharma Group International (AAPG.US) against any of the KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage was either explicitly stated as not available, not quantitative, or pertained to supplier policies rather than company performance.

While provides salary data for various roles and cost of living information for Rockville, it does not provide the percentage of the workforce earning a living wage, which is required by the rubric. and mention a lawsuit regarding alleged retaliation and wrongful termination, but this is a legal claim, not a substantiated labor law or human rights violation as defined by the rubric.

Fair Trade & Ethical Sourcing

The company conducts on-site audits for commissioned production of preparations once a year, and for higher risk materials or GMP services not less than once every two years.

It reported zero substantiated child or forced labor incidents in the last three years and explicitly opposes child and forced labor. The company has achieved 100% effective traceability of problematic drugs and materials within stipulated times during product recall drills, utilizing systems like Alibaba Health’s “Ma Shang Fang Xin Drug Traceability System” for listed drugs. For product recalls, the company aims to notify relevant parties within 24 hours for first-level, 48 hours for second-level, and 72 hours for third-level recalls. The company requires suppliers to make written commitments regarding business relationships and compliance events, and includes anti-corruption clauses in contracts.

Honest & Fair Business

Ascentage Pharma Group International reported zero ethics-related regulatory fines, bribery, or corruption lawsuits, and no environmental administrative penalties in the past three years (2022-2024).

The company has not had any financial restatements in the past five years. Its production facilities are 100% covered by ISO 9001 and ISO 14001 certifications, and product testing achieved 100% batch coverage with a 100% compliance rate. The company has a comprehensive anti-corruption policy, conducts annual training, and performs regular due diligence on suppliers based on risk ratings. In 2024, 11 online compliance trainings covered 279 participants, and new employees are required to complete anti-corruption courses. However, despite having a strict whistleblower protection policy, multiple reporting channels (email, website, hotline), and offering cash rewards, the company reported not receiving any compliance reports as of the end of 2024. The board of directors consists of 9 directors, with 6 independent non-executive directors, which is approximately 67% independent. The company engages a professional third-party audit team for quality management system gap analysis and simulation audits, uses third-party assessment agencies for new suppliers, and conducts professional construction audits for key fixed asset procurement. It also passed a four-star accreditation of Baidu’s enterprise certification.

Kind to Animals

The company has established an experimental animal ethics committee and an experimental animal management committee, which formulate regulations and systems for the administration of experimental animals.

The ethics committee focuses on strictly implementing the "3R principle" (Reduction, Replacement, and Refinement) for experimental animals, and all experimental proposals are reviewed and evaluated every half year. The management committee enforces internal operational requirements, organizes regular training for staff, and ensures employees are qualified with relevant certificates. It is stipulated that, in the absence of in vitro experimental data, animal experiments are forbidden, or other experimental methods must be used to replace animal experiments, or inferior experimental animals must be used instead of superior ones.

No War, No Weapons

The provided article from Sustainalytics explicitly states that it does not contain data relevant to Ascentage Pharma Group International (AAPG.US) for the 'No War, No Weapons' value.

It further clarifies that no quantitative data related to the specified metrics is available, focusing instead on general pharmaceutical industry ESG risks and management. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

The company's 2023 ESG Report, covering January 1, 2023, to December 31, 2023, states that no specific regulatory actions, violations, fines, or compliance issues were mentioned.

No other quantitative data for environmental metrics is provided in the available articles.

Respect for Cultures & Communities

The provided articles explicitly state that the sustainability reports are for Ascentage Pharma Group International and not for AAPG.US.

Therefore, no relevant data for AAPG.US could be extracted to assess its performance against the 'Respect for Cultures & Communities' value.

Safe & Smart Tech

Ascentage Pharma's privacy policy outlines user rights to access, correct, and delete their data, reflecting industry-standard user privacy controls.

The policy also mentions data deletion when data is no longer necessary, indicating standard data minimization practices. Furthermore, the company's privacy policy addresses compliance with GDPR, CCPA, and other relevant laws, demonstrating basic regulatory compliance.

Zero Waste & Sustainable Products

The company achieved a 94.4% reduction in waste plastic produced from 2021 to 2022.

Ascentage Pharma has implemented several waste reduction initiatives, including waste classification and recycle/reuse programs for employees, an updated Solid Waste Management System, a company-wide paperless office, and an empty plate campaign in the cafeteria. For hazardous waste, the company produced 59.25 tons in 2024 and 47.91 tons in 2023, with a target to achieve zero landfilling of hazardous waste by 2025. Hazardous wastes are handled by qualified disposal units. The company conducts monthly environmental monitoring on all R&D and production sites, covering 21 testing items and 579 samples in 2024, and performs two internal environmental audits annually. Ascentage Pharma has obtained ISO 14001 environmental management system certification, covering 100% of its production facilities, and Ascentage Suzhou secured approval as a 2A-level Green Factory in Suzhou Industrial Park for 2024, along with a 3A-level Green Factory certification. The company reported zero environmental pollution incidents and administrative penalties during the reporting period. It has a target to achieve a 95% waste recycling and reuse rate by 2040. The company prioritizes GMP suppliers with sound systems and environmental friendliness, such as those with environmentally friendly certifications, and gives priority to green logistics service providers.